Prostate Cancer Clinical Trial

PYLARIFY® PET/CT or PET/MRI in Men With Favorable Intermediate Risk (FIR) Prostate Cancer

Summary

The purpose of this study is to learn whether PYLARIFY PET imaging (study scan) can safely and accurately detect the presence or absence of prostate cancer growing beyond the prostate gland in men with favorable intermediate risk prostate cancer.

Participants will receive a single dose of PYLARIFY injection followed by a single whole-body PET/CT or PET/MRI scan acquired at 1 to 2 hours after PYLARIFY injection. Participants with positive study scan results that are suspicious for prostate cancer outside of the prostate gland may be asked to undergo additional diagnostic test(s) and/or recommend certain treatment(s) for prostate cancer within 2 to 90 days after the study scan. Participants will be monitored for up to 12 months to collecting information about treatment they receive for prostate cancer and results of regular PSA blood draws if ordered by doctors for up to 12 months after the study scan.

View Eligibility Criteria

Eligibility Criteria

Inclusion Criteria:

Patients must have the ability to understand and sign an approved informed consent form (ICF)
Patients must have the ability to understand and comply with all protocol requirements
Patients must be ≥ 18 years of age
Patients must have an Eastern Cooperative Oncology Group (ECOG) performance status of 0 to 2
Patients with life expectancy of at least 13 months as determined by the investigator

Patients must have confirmed favorable intermediate risk (FIR) adenocarcinoma of the prostate per 2023 NCCN guidelines. FIR risk group confirmation includes all the following:

1 intermediate risk factor (cT2b-cT2c or ISUP Grade Group 2 or PSA 10-20 ng/mL)
ISUP Grade Group 1 or 2
<50% biopsy cores positive (e.g., <6 of 12 cores)

Note: Date of the prostate biopsy should be no sooner that 2 weeks and no later than 3 months prior to PYLARIFY PET imaging

Exclusion Criteria:

Patients administered any high energy (>300 KeV) gamma-emitting radioisotope within 5 physical half-lives prior to Day 1 (PYLARIFY imaging)
Previous Prostate cancer treatment including radiation, androgen deprivation therapy, brachytherapy, surgery, prostate ablation, hormonal therapies or investigational therapy
Known hypersensitivity to the components of PYLARIFY or its analogs
Patients with any medical condition or other circumstances that, in the opinion of the investigator, compromise the safety or compliance of the subject to produce reliable data or complete the study
Patients who have any radiographic evidence of T3, N1 or M1 disease on SOC imaging (if performed)

Study is for people with:

Prostate Cancer

Phase:

Phase 4

Estimated Enrollment:

274

Study ID:

NCT06074510

Recruitment Status:

Recruiting

Sponsor:

Lantheus Medical Imaging

Check Your Eligibility

Let’s see if you might be eligible for this study.

What is your age and gender ?

Submit

There are 3 Locations for this study

See Locations Near You

Hoag Cancer Center
Irvine California, 92618, United States More Info
Danett Reynolds
Contact
949-557-0285
[email protected]
Gary Ulaner, MD
Principal Investigator
Tower Urology
Los Angeles California, 90048, United States More Info
Shiblee Nomanee
Contact
310-854-9898
[email protected]
Terry Williams
Contact
3108549898
[email protected]
David Josephson, MD
Principal Investigator
Cleveland Clinic
Cleveland Ohio, 44195, United States More Info
Yvette Walker
Contact
216-444-6120
[email protected]
Andrei Purysko, MD
Principal Investigator

How clear is this clinincal trial information?

Study is for people with:

Prostate Cancer

Phase:

Phase 4

Estimated Enrollment:

274

Study ID:

NCT06074510

Recruitment Status:

Recruiting

Sponsor:


Lantheus Medical Imaging

How clear is this clinincal trial information?

×

Introducing, the Journey Bar

Use this bar to access information about the steps in your cancer journey.